Skip to content

Clinical evaluation of the effects of esmolol and magnesium sulfate to avoid tachycardia and arterial hypertension during intubation in surgeries

Clinical evaluation of the effects of esmolol and magnesium sulphate on the hemodynamic response to tracheal intubation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
REBEC
Registry ID
RBR-9jqdgq
Enrollment
Unknown
Registered
2017-11-08
Start date
2017-04-18
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intubation and hemodynamic

Interventions

One hour before surgery, all patients selected will receive 15 mg of midazolam. Anesthesiologist will perform standard anesthetic induction using 3 mcg / kg of fentanyl, 2 mg / kg of propofol and 0.5
the second group will receive 1.5 mg / kg esmolol
and the third group will be the control group, which will use only 0.9% saline solution. After endotracheal intubation, all patients will be ventilated within the first 10 minutes at a tidal volume of
Drug

Sponsors

Universidade do Sul de Santa Catarina
Lead Sponsor
Hospital Nossa Senhora da Conceição
Collaborator

Eligibility

Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Functional class I and II patients, according to the American Society of Anesthesiologists (ASA); submitted to elective surgery; of both sexes; aged between 18 and 65 years; who agree to participate in the study

Exclusion criteria

Exclusion criteria: Patients with difficult airway; obesity with BMI> 35; in the use of beta-blockers or calcium channel blockers; with heart rate less than 60 bpm; cardiac arrhythmias, renal dysfunction, airway hyperreactivity, hypersensitivity to esmolol or magnesium sulfate; and pregnant women.

Design outcomes

Primary

MeasureTime frame
Hemodynamic stability with maintenance of blood pressure and heart rate baseline, assessed by cardioscopy and noninvasive blood pressure. The 20% variation of pressure levels and heart rate relative to the low levels is considered an unfavorable outcome.

Secondary

MeasureTime frame
Secondary outcomes are not expected

Countries

Brazil

Contacts

Public ContactFabiana Schuelter-Trevisol

Universidade do Sul de Santa Catarina

fastrevisol@gmail.com+55 (48)36317239

Outcome results

None listed

Source: REBEC (via WHO ICTRP)